← FDA DRUG APPROVALS

FDA ANDA · ANDA091099

IMIPRAMINE PAMOATE

Sponsor: HIKMA

APPLICATION
ANDA091099
TYPE
ANDA
ORIGINAL APPROVAL
2010-04-16
LATEST ACTION
2025-06-24
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription

Products

IMIPRAMINE PAMOATEPrescription
IMIPRAMINE PAMOATE EQ 100MG HYDROCHLORIDE · CAPSULE · ORAL
IMIPRAMINE PAMOATEPrescription
IMIPRAMINE PAMOATE EQ 125MG HYDROCHLORIDE · CAPSULE · ORAL
IMIPRAMINE PAMOATEPrescription
IMIPRAMINE PAMOATE EQ 75MG HYDROCHLORIDE · CAPSULE · ORAL
IMIPRAMINE PAMOATEPrescription
IMIPRAMINE PAMOATE EQ 150MG HYDROCHLORIDE · CAPSULE · ORAL

Approval history

2025-06-24Labeling · Supplement 6 · standardAP
2016-02-02Labeling · Supplement 3 · standardAP
2014-02-21Labeling · Supplement 2 · standardAP
2010-04-16OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →